Related Experiment Video

Updated: May 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Anti-platelet agents in pediatric cardiac practice

Sweta Mohanty1, Balu Vaidyanathan

  • 1Department of Pediatric Cardiology, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India.

Annals of Pediatric Cardiology
|April 30, 2013
PubMed

Insights

This review examines anti-platelet drug use in pediatric cardiac patients, highlighting that many current treatments lack robust evidence and are often based on adult data.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Thrombosis Management

Background:

  • Pediatric cardiac patients often require antithrombotic therapy for various conditions.
  • Current treatment guidelines are frequently based on empirical data or extrapolated from adult studies.
  • Evidence supporting specific anti-platelet drug indications in children is often limited.

Purpose of the Study:

  • To review the existing literature on anti-platelet drug utilization in pediatric cardiac patients.
  • To assess the evidence base for current antithrombotic strategies in this population.
  • To identify gaps in knowledge regarding anti-platelet therapy in pediatric cardiac conditions.

Main Methods:

  • Comprehensive literature search of relevant databases.
  • Systematic review of studies investigating anti-platelet agents in pediatric cardiac care.
  • Analysis of study designs, patient populations, and reported outcomes.

Main Results:

  • Limited controlled studies exist specifically for pediatric anti-platelet drug use.
  • Many indications are extrapolated from adult data, lacking pediatric-specific validation.
  • Variability in drug choice and dosing is observed across different pediatric cardiac conditions.

Conclusions:

  • There is a significant need for high-quality, pediatric-focused research on anti-platelet therapies.
  • Evidence-based guidelines are crucial to optimize antithrombotic treatment in children with heart disease.
  • Further investigation is required to establish efficacy and safety profiles of anti-platelet drugs in this vulnerable population.

Keywords:
Anti-platelet drugsanti-thrombotic therapypediatric cardiac practice

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...